SEQENS

OUR SCIENCE FOR YOUR FUTURE

PRESS RELEASE | ECULLY, FRANCE – October 5th, 2026

SEQENS Welcomes EU Anti-Dumping Investigation on Acetylsalicylic Acid

The European Commission has initiated an anti-dumping investigation into imports of acetylsalicylic acid (ASA) originating in China.

SEQENS supports open trade and fair competition, provided all market participants operate on a level playing field. The investigation is an important step toward assessing market conditions and trade practices through an independent, evidence-based process — one whose outcome it does not prejudge.

ASA is a critical pharmaceutical ingredient used in Aspirin and other essential healthcare applications. Maintaining a competitive, resilient European manufacturing base for key active pharmaceutical ingredients has long been a priority for SEQENS, essential to strengthening supply chain security, industrial resilience, and continued access to critical medicines.

SEQENS will fully cooperate with the European Commission throughout the process and remains committed to supporting a strong, innovative, and sustainable pharmaceutical manufacturing sector in Europe.

About SEQENS:

SEQENS is a world leader in the development and production of active pharmaceutical ingredients, intermediates and specialty ingredients, with 13 production sites, 3R&D centers and 2,100 employees on 3 continents.

As an integrated player across the entire value chain - from raw materials to active ingredients and from R&D to industrialization - SEQENS offers a broad portfolio of active pharmaceutical ingredients, pharmaceutical intermediates and specialty ingredients, develops and industrializes the most complex molecules, and leverages its ability to innovate, develop and implement the best available technologies.

SEQENS SAS - 21 chemin de la Sauvegarde, 21 Ecully Parc - CS 33167 - 69134 ECULLY Cedex - Share capital 226 890 746.63 euros - 444 465 736 00049 RCS Lyon - Tel : +33 (0)4 26 99 18 00 - Fax : +33 (0)4 26 99 18 38

OUR SCIENCE FOR YOUR FUTURE

Driven by a culture of excellence and a strong entrepreneurial spirit, our employees are committed to providing our customers with the highest level of service and quality, while acting ethically in accordance with our environmental, social and governance program.

press@seqens.com / www.seqens.com / LinkedIn: SEQENS

SEQENS SAS - 21 chemin de la Sauvegarde, 21 Ecully Parc - CS 33167 - 69134 ECULLY Cedex - Share capital 226 890 746.63 euros - 444 465 736 00049 RCS Lyon - Tel : +33 (0)4 26 99 18 00 - Fax : +33 (0)4 26 99 18 38